Schear Investment Advisers LLC Has $1.29 Million Stock Position in Stryker Co. (NYSE:SYK)

Schear Investment Advisers LLC increased its position in shares of Stryker Co. (NYSE:SYK) by 11.3% during the fourth quarter, Holdings Channel reports. The fund owned 3,582 shares of the medical technology company’s stock after acquiring an additional 365 shares during the quarter. Schear Investment Advisers LLC’s holdings in Stryker were worth $1,290,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dunhill Financial LLC lifted its holdings in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in Stryker in the 3rd quarter worth about $36,000. Activest Wealth Management purchased a new stake in Stryker in the 4th quarter worth about $36,000. Crews Bank & Trust acquired a new stake in Stryker during the 4th quarter worth about $39,000. Finally, Hara Capital LLC acquired a new position in shares of Stryker in the 3rd quarter valued at about $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.90% of the stock is currently owned by company insiders.

Stryker Stock Down 0.5 %

SYK opened at $390.52 on Wednesday. The business has a 50 day moving average of $377.28 and a 200-day moving average of $365.59. The stock has a market capitalization of $148.88 billion, a price-to-earnings ratio of 50.33, a P/E/G ratio of 2.98 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company posted $3.46 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio is currently 43.30%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SYK. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Evercore ISI boosted their price target on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. BTIG Research upped their target price on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group lifted their price target on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.